Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Patients diagnosed with Guillain-Barré syndrome were confirmed based on the diagnostic
criteria for Guillain-Barré syndrome. Patients who meet all inclusion criteria and do not
conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin)
400mg/kg/day for five consecutive days.
Patients evaluate the Functional Grade（FG） and Arm Grade（AG） et al.
As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse
events by the start of the study treatment.